Purchase Order 75N92024P00257
Award Date 8/5/24
Potential Completion Date 5/4/25
Potential Value $26K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10019, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $15,375 firm-fixed-price purchase order contract awarded by the National Human Genome Research Institute, a civilian agency within the Department of Health and Human Services, to the New York Stem Cell Foundation, Inc., a non-profit organization. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines from patients with Alzheimer's disease and related dementias, differentiating stem cells into insulin-producing beta cells,...
- This is a $361,950 firm fixed-price purchase order awarded by the National Human Genome Research Institute (NHGRI), a civilian agency within the National Institutes of Health (NIH), to the New York Stem Cell Foundation Inc., a non-profit organization and foundation. The contract is for the generation of induced pluripotent stem cells (iPSCs) and the differentiation of beta cells. The work will be performed in Bethesda, Maryland, and the contract has an ultimate completion date of September 24,...
- This is a $241,500 firm fixed price contract awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for the generation and characterization of human induced pluripotent stem cells (iPSCs), neural progenitor cells (NPCs), and stable transgenic iPSC lines from individuals with mood and anxiety disorders. This contract does not have a set-aside...
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $150,000.00 firm fixed-price purchase order contract to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines, differentiating stem cells into insulin-producing beta cells, and expanding and validating neural...
- This federal contract award from the National Human Genome Research Institute, an agency within the U.S. Department of Health and Human Services, was made to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract, valued at $425,000.00, is for the generation of 50 induced pluripotent stem cell (iPSC) lines from fusion study fibroblast cell lines. No set-aside designation was used for this contract. The New York Stem Cell Foundation Inc....
- This $238,000.00 firm-fixed price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to the New York Stem Cell Foundation, Inc., a non-profit organization that conducts stem cell research. The contract is for the derivation of induced pluripotent stem cells, which aligns with the foundation's work in generating stem cell lines, differentiating them into various cell types, and...
- Synthego Corporation has been awarded a firm fixed price purchase order valued at twenty-six thousand three hundred thirty dollars by the National Institute of Dental and Craniofacial Research within the Department of Health and Human Services. Under this contract, Synthego will supply induced pluripotent stem cell clones to the agency as requested in a January 2024 presolicitation notice seeking "Knockin-Small, Cell Clone, iPSC, Synthego Supplied VIAL." Performance will occur at...
- This is a $1,399,499.93 firm fixed-price definitive contract awarded by the National Eye Institute, a civilian agency within the Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The purpose of this contract is to obtain induced pluripotent stem cells (iPSCs) to advance the study of the functional basis of genetic variants associated with age-related macular degeneration (AMD). No set-aside designation was used for this award. The...
- This is a $1,405,000.00 firm fixed price purchase order contract awarded by the National Human Genome Research Institute, a component of the Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for services related to beta cell differentiation and cell assays, which aligns with the original solicitation that sought the development of assays to evaluate the differentiation of stem cells into insulin-producing beta cells. No...
- The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $150,000.00 firm fixed-price purchase order to 3Dnamics Inc., a biotechnology company, for services related to the differentiation and characterization of induced pluripotent stem cell (iPSC) lines. This non-competitive commercial item acquisition was conducted under simplified acquisition procedures without a small business set-aside. The services...
The National Institute of Dental and Craniofacial Research, a civilian agency within the Department of Health and Human Services, awarded a $26,250.00 firm fixed price purchase order to the New York Stem Cell Foundation Inc., a non-profit organization, to provide 3 patient-derived induced pluripotent stem cell (iPSC) lines with isogenic controls for the study of DiGeorge Syndrome (DGS). This contract was awarded under a broader solicitation seeking DGS patient-derived iPSCs to generate neural crest cells and derivatives for research on the effects of the DGS deletion mutation. The contract has a completion date of May 4, 2025 and did not utilize any set-aside designations.
Generated 8/6/24, 10:52 AM
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
DiGeorge Syndrome (DGS) Patient Derived iPSCs | 75N92024Q1031 | Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute | Solicitation 1/1 | 7/12/24, 1:58 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.3k | 8/5/24 |